相关实验视频

Updated: May 16, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

在风湿性心脏病中使用迪戈辛:多中心,安慰剂控制的双盲随机对照试验 (Dig-RHD试验) 的推理和设计

Niveditha Devasenapathy¹, Shyamashree Biswas¹, Prayaag Kini²

¹The George Institute for Global Health, New Delhi, India.

American heart journal

|May 14, 2025

概括

Dig-RHD试验是第一个用于治疗风湿性心脏病 (RHD) 的迪戈辛随机研究. 它将确定狄戈辛是否能改善RHD患者心力衰竭 (HF) 等临床结果.

科学领域:

心脏病学心脏病学
临床试验临床试验
公共卫生公共卫生

背景情况:

风湿性心脏病 (RHD) 是低收入和中等收入国家的重大公共卫生问题,导致心力衰竭 (HF),发病率和死亡率高.
目前的治疗指南缺乏来自随机试验的强有力的证据,专门针对RHD患者的HF管理.
迪戈辛素通常用于RHD,尽管对其临床有效性的数据有限.

研究的目的:

评估狄戈辛对RHD患者临床结果的影响.
提供第一个随机临床试验数据,以确定狄戈辛在RHD中的疗效.

主要方法:

一个多中心,务实,随机,安慰剂控制,平行臂优越性试验 (Dig-RHD).
有症状的成人RHD患者在常规护理中接受口服狄戈辛或安慰剂.
主要结局是所有原因死亡和新发病或恶化的HF的复合. 其次性结局包括死亡,HF住院和生活质量.

主要成果:

到2024年8月,印度12个学术医疗中心完成了1769人的患者入学.
数据安全监测委员会进行的一次临时安全审查显示,没有任何安全问题.
预计2025年12月将完成全部数据收集.

结论:

Dig-RHD试验代表了第一个基于临床结果的随机试验,用于RHD的迪戈辛使用.
预计研究结果将对全球RHD患者的标准管理产生重大影响.

关键词:

迪戈辛因 (Digoxin) 是一种可怕的药物.心脏衰竭是因为心脏衰竭.中心门的中心门.类风湿性心脏病类风湿性心脏病

更多相关视频

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...